Topic Archives: Macrogenics (MGNX)

Comments

  • Avatar

    Thanks for the details of the financial arrangement. I am reading this a pretty negative. My only explanation is the sa...

  • Avatar

    $PTN -- The Phase 3 trial results were great and well-predicted by Doc's column which came out a few weeks earlier. Addi...

  • DrKSSMDPhD

    Hi michmana: the overall NDA/BLA cost depends a lot on how they budget things internally, and they are secretive about i...

  • Avatar

    $PTN I do believe that PTN is looking like a possible buyout. However, the large number of shares/warrants limits the ...

  • Avatar

    $PTN: A negative SA piece on Addyi & Valeant. Keeping with the concept that the enemy of my enemies are my friend, ...

  • Avatar

    PTN: They have an approved product equiv to a female viagra....sales could be MASSIVE . If nothing else, the owners of A...

  • Avatar

    Yes, totally agree with what you say jabberwocky. The trouble with the "frenzy" of rumors etc...is that they can lead to...

  • DrKSSMDPhD

    Agree. The stars are aligned here, and people need to not miss out. $ARTH will do the same in due course, I feel, but sh...

  • DrKSSMDPhD

    I don't give directed personal investing advice, but I feel very obliged to point out and emphasize the opportunity in f...

  • DrKSSMDPhD

    A $PTN buyout is plausible. Flibanserin (Addyi) was recently approved for FSD and bought by Valeant....

  • Avatar

    $PTN New Roth report out today Roth Capital Affirms Palatin Technologies (PTN) at 'Buy'; Q1 Solid and Partnership Pot...

  • DrKSSMDPhD

    $500M US sales, $1.5B ex-US, $2B globally. If they hustle, they can have BLA approval for marketing in 1H2018 by submitt...

  • Avatar

    $PTN - - some observations from the presentation. > Slide 7: "Market analysts estimate global market > $2 billi...

  • Avatar

    Doc, could you clarify for me how the Phase 3 data for Bremelanotide shows that it's significantly more efficacious than...

  • Avatar

    My opinion is that due to PTN's shaky financial situation and the fact that Addyi has been an abject failure will make t...

  • Avatar

    Not to quibble with you, bizbanx. But recall that Valeant bought Sprout for $1 billion for an abysmal drug, Addyi, which...

  • Avatar

    $PTN Copied -----For what its worth--For me it confirms the importance of doing a transaction sooner than later---PTN ha...

  • Avatar

    $PTN Canaccord aanalyst report -- "Palatin shares are rising 30% after the company’s key pipeline drug bremelanotid...

  • Avatar

    Let the games and the price negotiations begin! I seriously doubt that $PTN will settle for anything short of $300 mill...

  • Avatar

    It certainly appears that $PTN has some offers on the table although we have no idea what they are. Logically, one woul...

  • Avatar

    $PTN Already has buy-out offers??? Exclusive: Female Viagra contender Palatin Technologies explores potential sa...

  • Avatar

    Definitely Doc, although I have to work and am on PST so probably cannot. IMO, the current share price is a steal (prob...

  • Avatar

    Thanks so much Doc for the helpful update and comments. $PTN shares have been falling rather significantly in recent day...

  • Avatar

    1) Gummies interested in evaluating how the FDA's Addyi approval process will read for $PTN might want to check out the...

  • Avatar

    Also from the $PTN conference call transcript, some comparison with Addyi: "s we look forward to top line data, we are w...

  • Avatar

    I also read that alcohol is compatible with bremelanotide whereas it's contraindicated in patients on flibanserin (Addyi...

  • Avatar

    Sprout Pharma was the company bought out by Valeant for $1 billion (mentioned in the article). I agree that Addyi is a ...

  • SoGiAm

    Author: JohnM Comment: http://www.stockgumshoe.com/2016/08/ten-common-biotech-investing-mistakes/comment-page-12/#comme...

  • JohnM

    $PTN no position Slingshot Insights upcoming call Bremelanotide Phase 3 Data Is Days Away In Female Sexual Dysfunction...

  • Avatar

    After the excitement that has been our last two data readouts ($AUPH, good news, bad reception; $CLCD, great), the next ...

  • DrKSSMDPhD

    You are sorely tempting me, Sharon. I suspect this one will fetch an ad com, and will be batted around, but will win app...

  • Avatar

    $PTN Been reading through the most recent conference call with Palatin, and things are looking interesting here. Both t...

  • Avatar

    The New York Times reports that Sprout's flibanserin - once dubbed the pink viagra - has proved less than arousing. Mar...

  • DrKSSMDPhD

    First some comments about Valeant. Its action in grabbing Addyi was proof, as if proof were needed, that a top was in fo...

  • Avatar

    $PTN. Was updating myself today on this stock, which has been discussed here from time to time, and am sharing in case ...

  • DrKSSMDPhD

    Hi Jonathan: I am actually studying that situation. My biggest concern is that EU partner Gedeon Richter pulled out of t...

  • Avatar

    Doc or anyone else, any thoughts about Palatin $PTN and maybe a potential buyout? No personal position currently, but ob...

  • DrKSSMDPhD

    Hi Curt: Not bremelanotide, but PTN has licenses to other brain-acting peptides that are believed to have potent appetit...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info